Tirzepatide has four FDA-approved indications: Mounjaro for type 2 diabetes (May 2022) and for cardiovascular risk reduction in type 2 diabetes (August 28, 2026), and Zepbound for obesity (November 2023) and obstructive sleep apnea (December 2024). Heart failure is not approved. Here is the complete tirzepatide FDA approval timeline, approved doses, and what comes next.
Tirzepatide is FDA approved under two brand names: Mounjaro (type 2 diabetes, May 2022; cardiovascular risk reduction in type 2 diabetes, August 2026) and Zepbound (obesity, November 2023; obstructive sleep apnea, December 2024). Heart failure (SUMMIT/HFpEF) and a cardiovascular indication for obesity without diabetes (SURMOUNT-MMO) are not approved.
Tirzepatide's dual GLP-1/GIP receptor agonism mechanism has enabled approvals across multiple metabolic indications. Each approval was supported by Phase 3 clinical evidence from Eli Lilly's SURPASS (diabetes) and SURMOUNT (obesity/metabolic) trial programs.
| Brand | Indication | Approval Date | Key Clinical Data |
|---|---|---|---|
| Mounjaro | Type 2 Diabetes | May 13, 2022 | HbA1c reduction of 1.87–2.59% vs 0.86–1.97% for semaglutide (SURPASS-2) |
| Zepbound | Chronic Weight Management (Obesity) | November 8, 2023 | 22.5% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg dose) |
| Zepbound | Obstructive Sleep Apnea | December 20, 2024 | 63% reduction in apnea-hypopnea index (SURMOUNT-OSA) |
| Mounjaro | Cardiovascular risk reduction in type 2 diabetes (high-risk adults) | August 28, 2026 | SURPASS-CVOT, >13,000 adults vs Trulicity (dulaglutide): non-inferior, 8% lower MACE rate (HR 0.92) |
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
First-in-human studies. Safety, tolerability, and pharmacokinetics established in healthy volunteers and T2D patients.
Dose-ranging in T2D patients. Established the 5 mg, 10 mg, 15 mg dose ladder. Strong HbA1c and weight reduction signals.
SURPASS 1–5: tirzepatide vs placebo, semaglutide, insulin degludec, and insulin glargine. All primary endpoints met.
FDA approved tirzepatide (Mounjaro) for type 2 diabetes. Breakthrough Therapy designation granted. Priority Review.
SURMOUNT-1: 22.5% mean weight loss at 72 weeks vs 2.4% placebo (p<0.001). SURMOUNT-2: T2D with obesity, 15.7% weight loss.
FDA approved tirzepatide (Zepbound) for chronic weight management. First dual GLP-1/GIP agonist approved for obesity.
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug approved for this indication.
FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, based on SURPASS-CVOT (head-to-head vs Trulicity; HR 0.92, non-inferior).
SUMMIT trial: 38% reduction in worsening heart-failure events or cardiovascular death in adults with HFpEF and obesity. No FDA approval for heart failure as of 24 October 2026.
SURMOUNT-MMO: cardiovascular outcomes trial in adults with obesity without T2D. Estimated completion 2026. Potential CV indication approval 2027.
A common source of confusion is that Mounjaro and Zepbound are the same medication — tirzepatide — at the same doses, manufactured by the same company (Eli Lilly). The FDA requires separate approvals for separate indications, which is why tirzepatide has two brand names. The practical difference for patients is primarily insurance coverage: Mounjaro is covered by most insurance plans for type 2 diabetes, while Zepbound coverage for obesity-only patients is more variable and often requires prior authorization.
Off-label use for weight loss is common but not covered by insurance for obesity-only patients.
Eligible if BMI ≥30 or ≥27 with a weight-related condition (hypertension, T2D, dyslipidemia, sleep apnea).
The FDA-approved titration schedule for tirzepatide starts at 2.5 mg once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated. The approved maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg and 7.5 mg doses are titration steps only. Slower titration (every 6–8 weeks) is commonly used off-label to reduce nausea during dose escalation.
| Week | Dose | Step Type | Notes |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg/wk | Initiation | Starting dose only — not a maintenance dose |
| Weeks 5–8 | 5 mg/wk | Titration / Maintenance | First maintenance dose; some patients stay here long-term |
| Weeks 9–12 | 7.5 mg/wk | Titration | Titration step only — not a maintenance dose |
| Weeks 13–16 | 10 mg/wk | Titration / Maintenance | Second maintenance dose option |
| Weeks 17–20 | 12.5 mg/wk | Titration | Titration step only — not a maintenance dose |
| Week 21+ | 15 mg/wk | Maximum Maintenance | Maximum approved dose; highest efficacy (22.5% weight loss in SURMOUNT-1) |
Eli Lilly is pursuing additional FDA approvals for tirzepatide beyond the four current indications. The cardiovascular approval so far covers type 2 diabetes only (SURPASS-CVOT); SURMOUNT-MMO tests cardiovascular outcomes in adults with obesity without diabetes.
38% reduction in worsening heart-failure events or cardiovascular death in adults with HFpEF and obesity, with improved symptoms and physical function. Not FDA-approved for heart failure as of 24 October 2026.
Primary endpoint: reduction in major adverse cardiovascular events (MACE) in adults with obesity without T2D. If positive, would be the first obesity drug with proven CV benefit.
Liver fibrosis and NASH resolution endpoints. GLP-1/GIP agonism has shown strong liver fat reduction in earlier trials.
Renal outcomes data from SURPASS-CVOT showed promising kidney protection signals. Dedicated CKD trial not yet announced.
| Agent | FDA Status | Approved Indications | Mean Weight Loss | Mechanism |
|---|---|---|---|---|
| Semaglutide | Approved | T2D (2017), Obesity (2021), CV risk (2023) | ~15% | GLP-1 agonist |
| Tirzepatide | Approved | T2D (2022), Obesity (2023), Sleep Apnea (2024), CV risk in T2D (2026) | ~22.5% | GLP-1 + GIP dual agonist |
| Retatrutide | Phase 3 | Not approved; Lilly plans to file Q1 2027 | ~24% (Phase 2) | GLP-1 + GIP + Glucagon triple agonist |
Yes. Tirzepatide has two FDA-approved brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management in adults with obesity or overweight with a weight-related condition). Both are manufactured by Eli Lilly and contain the same active ingredient — tirzepatide — at the same doses.
Mounjaro and Zepbound contain identical active ingredients (tirzepatide) at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes management (blood sugar control), while Zepbound is approved for chronic weight management (obesity). Insurance coverage differs significantly between the two — Zepbound coverage for obesity is more limited than Mounjaro coverage for T2D.
Tirzepatide (Mounjaro) was first FDA approved on May 13, 2022, for adults with type 2 diabetes as an adjunct to diet and exercise to improve blood sugar control. Tirzepatide (Zepbound) received a second FDA approval on November 8, 2023, for chronic weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² with at least one weight-related condition such as hypertension or dyslipidemia.
The FDA-approved tirzepatide titration schedule starts at 2.5 mg once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, up to a maximum dose of 15 mg once weekly. The maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg and 7.5 mg doses are titration doses only and are not intended as long-term maintenance doses.
As of 24 October 2026: the obstructive sleep apnea indication is approved (Zepbound, December 20, 2024), and on August 28, 2026 the FDA approved Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes (SURPASS-CVOT). Not yet approved: heart failure (SUMMIT, HFpEF plus obesity), a cardiovascular indication for obesity without diabetes (SURMOUNT-MMO), and liver disease (MASH).
Not yet. In the Phase 3 SUMMIT trial, tirzepatide reduced the risk of worsening heart-failure events or cardiovascular death by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity, and improved symptoms and physical function. As of 24 October 2026 tirzepatide is not FDA-approved for heart failure. The approved indications are type 2 diabetes, cardiovascular risk reduction in type 2 diabetes, obesity, and obstructive sleep apnea.
Research-grade tirzepatide is available from verified suppliers like Purgo Labs for research purposes only. This is distinct from the FDA-approved prescription medications Mounjaro and Zepbound, which require a prescription from a licensed healthcare provider. Research-grade tirzepatide from Purgo Labs comes with third-party COAs confirming ≥99% purity.
Semaglutide (Ozempic/Wegovy) was FDA approved for T2D in 2017 and for obesity in 2021. Tirzepatide (Mounjaro/Zepbound) was approved for T2D in 2022 and obesity in 2023. Retatrutide is not yet FDA approved — it is in Phase 3 trials with an estimated approval date of 2027–2028. Tirzepatide's dual GLP-1/GIP mechanism produces ~22% weight loss vs ~15% for semaglutide, and retatrutide's triple agonism (GLP-1/GIP/glucagon) produced ~24% in Phase 2 trials.
Purgo Labs provides research-grade tirzepatide with third-party COAs from accredited US labs confirming ≥99% purity. Code HEALTH is 20% off every order at Purgo Labs (verified recurring).
Shop Purgo LabsUse code HEALTH for 20% off · Research use only